Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia

NCT00251368 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Leukemia, Myelocytic, Acute
Acute Lymphocytic Leukemia

Interventions

DRUG: 9-Aminocamptothecin (9-AC)

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]
[object Object]